ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L19

A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

George Spencer-Green1, David Hunter2, Thomas Schnitzer3, Sheue-Fang Shih4, Tien-Tzu Tai4, Cathy Kao4 and Siao-Ning Huang4, 1Taiwan Liposome Company, Cambridge, MA, 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Taiwan Liposome Company, Taipei, Taiwan (Republic of China)

Meeting: ACR Convergence 2023

Date of first publication: October 24, 2023

Keywords: corticosteroids, Late-Breaking 2023, Osteoarthritis, Outcome measures, pain, WOMAC

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 15, 2023

Title: Late-Breaking Abstract Session

Session Type: Late-Breaking Abstract Session

Session Time: 7:30AM-9:00AM

Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable, and the duration of pain relief can be short. The benefit of repeat injection has not been established. TLC599 is a liposomal formulation of dexamethasone sodium phosphate (DSP) intended for administration by local injection to provide sustained relief of pain of OA of the knee. The current study was conducted to confirm earlier phase 2 results demonstrating pain relief in OA patients over 24 weeks (Hunter et al., 2022), and to study the benefit of repeat injection over one year.

Methods: The study was a Phase 3, randomized, double-blinded, 3-armed, placebo- and active-controlled study to evaluate the efficacy and safety of TLC599 in single or repeat doses, in patients with K-L Grade 2-3 OA of the knee and average daily pain (ADP) from screening diary completion in the index knee of 5-9 (on a scale of 0-10). A total of 506 patients were randomized in a 2:1:1 ratio to receive an injection of TLC599 12 mg, DSP 4 mg, or saline placebo. At Week 24, eligible patients in the TLC599 and placebo arms received a second blinded injection of the same treatment, while patients in the DSP arm received a blinded injection of TLC599. Efficacy and safety were assessed through Week 52. Among other efficacy parameters, ADP and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain were assessed using Mixed Models for Repeated Measures (MMRM) and Analysis of Covariance (ANCOVA), respectively.

Results: With respect to WOMAC pain, TLC599 was numerically superior to placebo at all time points through week 24, and statistically superior (p< 0.05) at Week 12, the primary endpoint. For ADP, TLC599 was numerically and statistically superior (p< 0.05) to placebo at all time points during Injection 1 period (Figure).Additionally, at Week 12, the reduction in ADP for TLC599 was superior to DSP (p< 0.05). A total of 203 patients who received an initial injection of TLC599 and 94 patients who received an initial injection of placebo were eligible and received repeat doses of TLC599 or placebo. The mean reduction in ADP from the injection 1 baseline for TLC599 was numerically superior to placebo at all time points through Week 52 and statistically superior through Week 34. TLC599 was generally well tolerated, with the number and type of adverse events similar among all three treatment groups. At Weeks 1 and 25 (after the second injection), there was a transient reduction in mean morning serum cortisol levels in patients who received TLC599, but this returned to normal by Weeks 2 and 26. There were no signs or symptoms of adrenal insufficiency in any patient.

Conclusion: TLC599 demonstrated a benefit over placebo in ADP and WOMAC pain in patients with OA of the knee after a single injection that was sustained to 24 weeks.A second injection of TLC599 at Week 24 provided further benefit to Week 52. These results provide additional information about the benefits of repeat steroid injection in OA of the knee and suggest that TLC599 may provide prolonged benefit and offer an alternative treatment for the management of OA knee pain.

Supporting image 1

Change from Injection 1 Baseline in Average Daily Pain (ADP) Score of Patients Who Received the First Injection through Week 24 (N=504) and Patients Who Received a Repeat Injection from Week 24 through Week 52 (N=297)


Disclosures: G. Spencer-Green: Taiwan Liposome Company, 3; D. Hunter: None; T. Schnitzer: AstraZeneca, 1, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Horizon, 1, IBSA, 2, KolonTissueGeme, 5, Merck, 2, Moebius, 2, Orion, 2, Paradigm, 2, 5, Pfizer, 2, Regeneron, 2, 5, TLC, 5, Xalud, 2; S. Shih: Taiwan Liposome Company, 3, 10, 11; T. Tai: Taiwan Liposome Company, 3, 10, 11; C. Kao: Taiwan Liposome Company, 3; S. Huang: Taiwan Liposome Company, 3.

To cite this abstract in AMA style:

Spencer-Green G, Hunter D, Schnitzer T, Shih S, Tai T, Kao C, Huang S. A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-phase-3-study-of-repeat-injection-of-tlc599-in-osteoarthritis-of-the-knee-benefits-to-52-weeks/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-3-study-of-repeat-injection-of-tlc599-in-osteoarthritis-of-the-knee-benefits-to-52-weeks/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology